Drug Patents owned by Cubist Pharms Llc

1. Drug name - CUBICIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage Sep, 2028

(5 years from now)

US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods Nov, 2030

(8 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL POWDER;INTRAVENOUS Discontinued
500MG/VIAL POWDER;INTRAVENOUS Prescription

2. Drug name - DIFICID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8586551 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jul, 2023

(9 months from now)

US7378508 CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jul, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

CN102746353A CUBIST PHARMS LLC Macro-Cyclic Polymorphic Substance, Composition With This Macro-Cyclic Polymorphic Substance, Usage And Preparation Method Thereof
May, 2016

(6 years ago)

CN101340919B CUBIST PHARMS LLC Method Of Treating Clostridium Difficile Associated Diarrhea
Dec, 2017

(4 years ago)

CN101340919A CUBIST PHARMS LLC Method Of Treating Clostridium Difficile-Associated Diarrhea
Dec, 2017

(4 years ago)

CN100519757C CUBIST PHARMS LLC Preparation Of Tiacumicins
Jul, 2023

(9 months from now)

CN1688707A CUBIST PHARMS LLC Preparation Of Table Hook
Jul, 2023

(9 months from now)

CN102614207B CUBIST PHARMS LLC 18 Membered Macrocyclic Compounds And Analogues Thereof
Jan, 2025

(2 years from now)

CN102614207A CUBIST PHARMS LLC 18-Membered Macrocyclic Compound And Analog Thereof
Jan, 2025

(2 years from now)

CN101128114B CUBIST PHARMS LLC 18 Membered Macrocyclic Compounds And Analogues Thereof
Jan, 2025

(2 years from now)

CN101128114A CUBIST PHARMS LLC 18-Membered Macrocycles Compound And Analogs
Jan, 2025

(2 years from now)

CN101663312B CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof
Jan, 2028

(5 years from now)

CN101663312A CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof
Jan, 2028

(5 years from now)

EP2070530B1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP1765312A2 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP1765312A4 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2305245A1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP1765312B1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2070530A1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2305244A1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2305245B1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP2305244B1 CUBIST PHARMS LLC Treatment Of Diseases Associated With The Use Of Antibiotics
May, 2025

(2 years from now)

EP1539977A2 CUBIST PHARMS LLC Tiacumicin Production
Dec, 2026

(4 years from now)

EP1539977A4 CUBIST PHARMS LLC Tiacumicin Production
Dec, 2026

(4 years from now)

EP1539977B1 CUBIST PHARMS LLC Tiacumicin Production
Dec, 2026

(4 years from now)

EP3412678A1 CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof
Jan, 2028

(5 years from now)

EP2125850A1 CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, Methods Of Manufacture And Use Thereof
Jan, 2028

(5 years from now)

EP2125850B1 CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, Methods Of Manufacture And Use Thereof
Jan, 2028

(5 years from now)

EP3412678B1 CUBIST PHARMS LLC Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof
Jan, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof Jan, 2024

(1 year, 3 months from now)

US7906489 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof Mar, 2027

(4 years from now)

US8859510 CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jul, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jul, 2027

(4 years from now)

US7906489

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof Sep, 2027

(4 years from now)

US7378508

(Pediatric)

CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B Jan, 2028

(5 years from now)

US8859510

(Pediatric)

CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jan, 2028

(5 years from now)

US7863249

(Pediatric)

CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jan, 2028

(5 years from now)

US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds May, 2034

(11 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds Nov, 2034

(12 years from now)

Drugs and Companies using FIDAXOMICIN ingredient

Treatment: Treatment of microbial infections; treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

3. Drug name - SIVEXTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(5 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(5 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(8 years from now)

CN102439006A CUBIST PHARMS LLC Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate
Jun, 2017

(5 years ago)

CN102516238A CUBIST PHARMS LLC Novel Derivatives Of Oxazolidinone
Dec, 2021

(8 months ago)

CN1894242A CUBIST PHARMS LLC New Oxazolidone Derivative
Dec, 2021

(8 months ago)

CN102702184B CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2021

(8 months ago)

CN1894242B CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2021

(8 months ago)

CN102516238B CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2021

(8 months ago)

CN102702184A CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2021

(8 months ago)

CN101982468A CUBIST PHARMS LLC An Oxazolidinone Derivative And Pharmaceutical Composition Comprising The Same
Jan, 2022

(8 months ago)

CN101982468B CUBIST PHARMS LLC Oxazolidinone Derivatives And Pharmaceutical Composition Containing The Derivative
Jan, 2022

(8 months ago)

IN200602167P4 CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

IN236862B CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

EP2305657B1 CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

EP2305657A3 CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

EP2305657A2 CUBIST PHARMS LLC Oxazolidinone Derivatives
Dec, 2024

(2 years from now)

EP1699784B1 CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2029

(7 years from now)

EP1699784A4 CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2029

(7 years from now)

EP1699784A1 CUBIST PHARMS LLC Novel Oxazolidinone Derivatives
Dec, 2029

(7 years from now)

EP2393808B1 CUBIST PHARMS LLC Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate
Feb, 2030

(7 years from now)

EP2393808A1 CUBIST PHARMS LLC Crystalline Form Of R)-3-(4-(2-(2-Methyltetrazol-5-Yl)Pyridin-5-Yl)-3-Fluorophenyl)-5-Hydroxymethyl Oxazolidin-2-One Dihydrogen Phosphate
Feb, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate Feb, 2030

(7 years from now)

US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate Feb, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

4. Drug name - ZERBAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7129232 CUBIST PHARMS LLC Cephem compounds
May, 2028

(5 years from now)

US8685957 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

US8476425 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

US8906898 CUBIST PHARMS LLC Solid forms of ceftolozane
May, 2034

(11 years from now)

CN100343260C CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 26 days from now)

CN1708502A CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 26 days from now)

IN200500936P2 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 26 days from now)

IN212088B CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 26 days from now)

EP1556389A1 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 27 days from now)

EP1556389B9 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 27 days from now)

EP1556389B3 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 27 days from now)

EP1556389B1 CUBIST PHARMS LLC Cephem Compounds
Oct, 2023

(1 year, 27 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028963 CUBIST PHARMS LLC Methods for treating intrapulmonary infections Sep, 2032

(9 years from now)

US9724353 CUBIST PHARMS LLC Methods for treating intrapulmonary infections Sep, 2032

(9 years from now)

US9320740 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions Mar, 2034

(11 years from now)

US9872906 CUBIST PHARMS LLC Ceftolozane antibiotic compositions Mar, 2034

(11 years from now)

US8968753 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions Mar, 2034

(11 years from now)

US10420841 CUBIST PHARMS LLC Ceftolozane antibiotic compositions Mar, 2034

(11 years from now)

US10376496 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function Sep, 2034

(11 years from now)

US10933053 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function Sep, 2034

(11 years from now)

US10125149 CUBIST PHARMS LLC Synthesis of cephalosporin compounds Aug, 2035

(12 years from now)

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

Treatment: Treatment of ventilator-associated bacterial pneumonia; treatment of hospital-acquired bacterial pneumonia; Treatment of complicated urinary tract infection, including pyelonephritis; treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection; treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.